Four deaths lead to suspension of clinical trial for autoimmune kidney disease treatment
- Kezar Life Sciences halts trial of lupus-nephritis treatment after four patient deaths
- Independent data monitoring committee recommends suspension
- Review found common pattern of symptoms and proximity to dosing in fatalities
- Phase 2a Portola trial for autoimmune hepatitis remains active with no Grade 4 or 5 serious adverse events
Kezar Life Sciences has voluntarily suspended enrollment and dosing in a clinical trial of zetomipzomib, a treatment for lupus nephritis, following the recommendation of an independent data monitoring committee. The review assessed deaths of patients in the Philippines and Argentina. Out of 84 patients enrolled in the Palizade trial, three fatalities showed a common pattern of symptoms and proximity to dosing, along with additional non-fatal serious adverse events. Kezar Life Sciences has not observed any instances of death or serious opportunistic infections in prior clinical studies of zetomipzomib. The company is notifying study investigators and regulatory authorities, including the FDA and EMA.
Factuality Level: 8
Factuality Justification: The article provides accurate information about the suspension of enrollment and dosing in a clinical trial due to patient deaths, mentions the independent data monitoring committee’s recommendation, and discusses the ongoing Portola trial without any sensationalism or opinion masquerading as fact. It also includes relevant details about the symptoms observed and notifications made to regulatory authorities.
Noise Level: 2
Noise Justification: The article provides relevant information about the suspension of enrollment in a clinical trial due to patient deaths and the company’s response, including notifying regulatory authorities. It does not contain irrelevant or misleading information, nor does it reinforce popular narratives without questioning them. The article stays on topic and supports its claims with evidence (the number of patients enrolled, the pattern of symptoms in fatalities, and the ongoing Portola trial). However, it could provide more analysis or context about the implications for the field of autoimmune disease treatments.
Public Companies: Kezar Life Sciences (KZR)
Key People:
Financial Relevance: Yes
Financial Markets Impacted: Kezar Life Sciences stock price and pharmaceutical industry
Financial Rating Justification: The article discusses a suspension of a clinical trial due to patient deaths, which can impact the company’s stock price and potentially affect the pharmaceutical industry as a whole.
Presence Of Extreme Event: Yes
Nature Of Extreme Event: Major Accident
Impact Rating Of The Extreme Event: Severe
Extreme Rating Justification: Four patients died in a clinical trial due to a common pattern of symptoms and proximity to dosing, causing the suspension of enrollment and dosing. This indicates a severe impact on the participants and the trial itself.
Move Size: No market move size mentioned.
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks
www.marketwatch.com 
